• Home
  • Search
  • Browse Collections
  • My Account
  • About
  • DC Network Digital Commons Network™
Skip to main content
Beaumont Health Scholarly Works and Archives
Beaumont Scholarly Works
  • My Account
  • FAQ
  • About
  • Home

Home > DEPARTMENTS > PHARMACY > PHARMACY_POSTERS

Posters

 
Printing is not supported at the primary Gallery Thumbnail page. Please first navigate to a specific Image before printing.

Follow

Switch View to Grid View Slideshow
 
  • Tenecteplase for Acute Ischemic Stroke: Insights from a Large Community Teaching Hospital by Ithar Alsarraf, Jennifer Pilotto, Rebecca E. Baker, and Emily Reich

    Tenecteplase for Acute Ischemic Stroke: Insights from a Large Community Teaching Hospital

    Ithar Alsarraf, Jennifer Pilotto, Rebecca E. Baker, and Emily Reich

    Publication Date: 12-2024

    Acute Ischemic Stroke (AIS) is a leading cause of disability and death in the United States, requiring urgent treatment1,2; earlier treatment improves patient outcomes.

    Fibrinolytic agents including alteplase and tenecteplase (TNK) reduce long-term disability in AIS but are associated with hemorrhagic risks3,4.

    As of January 2024, Corewell Health East hospitals updated their guidelines that TNK would be the first line agent in the treatment of AIS.

    Alteplase is the only approved agent for AIS, but TNK shows similar effectiveness along with shorter preparation and administration time which may ultimately improve door-to-needle time2 .

    Careful consideration of patient characteristics is important to minimize hemorrhagic risk: blood pressure (BP), surgical history, head imaging, medications prior to symptom onset, and National Institutes of Health Stroke Scale (NIHSS).

    The American Heart Association (AHA) and American Stroke Association (ASA) recommend a door-to needle time of 60 minutes or less, and a medication order entry to thrombolytic treatment of 45 minutes or less1,2.

  • Multidisciplinary Approach to Pulmonary Arterial Hypertension Therapy Transition: A Patient Case Report by Jacqueline Brewer, Tania Saeed, and Bhavinkumar Dalal

    Multidisciplinary Approach to Pulmonary Arterial Hypertension Therapy Transition: A Patient Case Report

    Jacqueline Brewer, Tania Saeed, and Bhavinkumar Dalal

    Publication Date: 10-2024

    Pulmonary arterial hypertension (PAH) is a rare, incurable disease that causes vasoconstriction of the pulmonary vasculature

    Therapy goals include improving hemodynamics as well as alleviating symptoms

    Therapies range from injectable to inhaled to oral to parenteral

    PAH treatment teams often transition between the various forms of therapies to reach therapy goals but also to improve patient’s quality of life

    The use of a supportive, multidisciplinary team approach, including physicians, nurse practitioners (NP), pharmacists, and nurses during these therapy transition phases is beneficial to achieve success and improve patient care

  • Evaluation of peri-operative antibiotic prophylaxis in patients undergoing total joint hip or knee arthroplasty by Heidi Klotz, Lauren Kassab, Muddasser Saiyed-Javed, Sandra Hartnagle, and Sapna Shah

    Evaluation of peri-operative antibiotic prophylaxis in patients undergoing total joint hip or knee arthroplasty

    Heidi Klotz, Lauren Kassab, Muddasser Saiyed-Javed, Sandra Hartnagle, and Sapna Shah

    Publication Date: 12-6-2023

  • Evaluation of asymptomatic bacteriuria treatment by Klea Noskey, Brian Bui, Selena Hailo, Katherine Bassil, Jennifer Pilotto, and Sandra Hartnagle

    Evaluation of asymptomatic bacteriuria treatment

    Klea Noskey, Brian Bui, Selena Hailo, Katherine Bassil, Jennifer Pilotto, and Sandra Hartnagle

    Publication Date: 12-6-2023

  • Transition of continuous intravenous epoprostenol to oral treprostinil in a patient with pulmonary arterial hypertension: A patient case report by Tania Saeed, Heidi Klotz, Klea Noskey, Jacqueline Brewer, Samuel Allen, and Rebecca Baker

    Transition of continuous intravenous epoprostenol to oral treprostinil in a patient with pulmonary arterial hypertension: A patient case report

    Tania Saeed, Heidi Klotz, Klea Noskey, Jacqueline Brewer, Samuel Allen, and Rebecca Baker

    Publication Date: 9-28-2023

  • Impact of Continuous Infusion Ketamine as Sedation on Concomitant Opioid and Sedative Requirements in Mechanically Ventilated COVID-19 Patients by Gabrielle R. Bradley, Megan Cadiz, and Allycia Natavio

    Impact of Continuous Infusion Ketamine as Sedation on Concomitant Opioid and Sedative Requirements in Mechanically Ventilated COVID-19 Patients

    Gabrielle R. Bradley, Megan Cadiz, and Allycia Natavio

    Publication Date: 12-7-2022

    Characterize the impact of continuous infusion ketamine (CIK) on concomitant opioid and sedative requirements in mechanically ventilated COVID-19 patients

  • Levetiracetam for Seizure Prophylaxis in Spontaneous Intracerebral Hemorrhage by Alanah Bratley, Krystal Commons, and Allycia Natavio

    Levetiracetam for Seizure Prophylaxis in Spontaneous Intracerebral Hemorrhage

    Alanah Bratley, Krystal Commons, and Allycia Natavio

    Publication Date: 12-7-2022

    Characterize the use of levetiracetam for early seizure prophylaxis in patients with sICH

  • Pharmacist-Provided Educational Intervention and its Impact on Medical Resident Knowledge and Comfort Level with Continuous Glucose Monitors (CGMs) by Chelsea Dezfuli, Sarah Muench, and Colleen Lauster

    Pharmacist-Provided Educational Intervention and its Impact on Medical Resident Knowledge and Comfort Level with Continuous Glucose Monitors (CGMs)

    Chelsea Dezfuli, Sarah Muench, and Colleen Lauster

    Publication Date: 12-7-2022

    Continuous glucose monitors (CGMs) have become an integral component of diabetes care

    American Diabetes Association now recommends that CGMs be offered to all patients on insulin who can use the device safely

    Integrating CGMs into clinical practice can be challenging for several reasons: – Data overload – Cost – Need for education on data interpretation

  • Evaluation of Antimicrobial Prophylaxis in Spine Surgery within an Enhanced Recovery Program at a Large Community Teaching Hospital by Sabrina DiPietro, Klea Noskey, Richard Zoltowski, Tania Saeed, and Sapna Shah

    Evaluation of Antimicrobial Prophylaxis in Spine Surgery within an Enhanced Recovery Program at a Large Community Teaching Hospital

    Sabrina DiPietro, Klea Noskey, Richard Zoltowski, Tania Saeed, and Sapna Shah

    Publication Date: 12-7-2022

    The risk of surgical site infections post spine surgery is 0% to 18%.1

    • American Society of Health System Pharmacists (ASHP) and Enhanced Recovery After Surgery (ERAS) Society guidelines recommend using an agent with activity against the most common surgical site pathogens including Staphylococcus aureus. 2,3

    • The preferred agent is cefazolin 2 grams intravenous (IV) (3 grams if patient weighs ≥120 kilograms [kg]) administered 30 minutes prior to skin incision and re-dosed every four hours intraoperatively.2,3

    • In the case of a cephalosporin allergy, clindamycin 900 milligrams (mg) IV or vancomycin 15 mg/kg IV are recommended alternatives.2,3

    • Due to lack of appropriate documentation of allergies in the electronic medical record (EMR), alternative antimicrobials are often prescribed.

  • Impact of Soy-Based Versus Composite Lipid Emulsion (Soybean, Medium Chain Triglycerides, Olive and Fish Oil) in Critically Ill Patients by Sandra Kless, Lisa Hall Zimmerman, and Olaf Kroneman

    Impact of Soy-Based Versus Composite Lipid Emulsion (Soybean, Medium Chain Triglycerides, Olive and Fish Oil) in Critically Ill Patients

    Sandra Kless, Lisa Hall Zimmerman, and Olaf Kroneman

    Publication Date: 3-2022

  • Evaluation of Antibiotic Selection and Duration in Patients with Non-Severe Community Acquired Pneumonia by Emily Reich, Sandra Hartnagle, Jennifer Pilotto, Heidi Klotz, and Ryan Herc

    Evaluation of Antibiotic Selection and Duration in Patients with Non-Severe Community Acquired Pneumonia

    Emily Reich, Sandra Hartnagle, Jennifer Pilotto, Heidi Klotz, and Ryan Herc

    Publication Date: 12-7-2022

  • Evaluation of Safety Outcomes of Two Hydrocortisone Dosing Regimens in Patients in Septic Shock by Alexandra Rola, Joshua Wirtz, Daniel Kalaj, Vasil Rrushi, and Megan Cadiz

    Evaluation of Safety Outcomes of Two Hydrocortisone Dosing Regimens in Patients in Septic Shock

    Alexandra Rola, Joshua Wirtz, Daniel Kalaj, Vasil Rrushi, and Megan Cadiz

    Publication Date: 12-7-2022

    • Steroids are used in shock to minimize the impact of shock-induced dysregulation of inflammatory response – Hydrocortisone is preferred for its activity as a glucocorticoid and a mineralocorticoid • Available data on the use of hydrocortisone shows mixed benefit – Data to guide dosing is limited, use of 100 mg IV every 8 hours may have benefit over 50 mg IV every 6 hours • Use of steroids has been associated with potential risks, including gastrointestinal bleeding, hyperglycemia, hypernatremia, superinfection, etc.

  • Ertapenem Versus Meropenem for the Treatment of ESBL-Producing Enterobacterales Bacteremia in Critically Ill Patients by Sydney VanDorf, Prakash Shah, Chad Richardson, and Christine Yost

    Ertapenem Versus Meropenem for the Treatment of ESBL-Producing Enterobacterales Bacteremia in Critically Ill Patients

    Sydney VanDorf, Prakash Shah, Chad Richardson, and Christine Yost

    Publication Date: 12-7-2022

    The purpose of this study is to evaluate clinical outcomes for critically ill patients receiving ertapenem or meropenem for ESBL-producing Enterobacterales bacteremia.

  • Safety Evaluation of Intravenous Heparin Protocol Following Alteplase Treatment in Patients with Suspected or Confirmed Pulmonary Embolism by Erika Waldsmith, Lisa Hall Zimmerman, and Claudia Hanni

    Safety Evaluation of Intravenous Heparin Protocol Following Alteplase Treatment in Patients with Suspected or Confirmed Pulmonary Embolism

    Erika Waldsmith, Lisa Hall Zimmerman, and Claudia Hanni

    Publication Date: 12-7-2022

 
 
 

Browse

  • Collections
  • Disciplines
  • Authors

Search

Advanced Search

  • Notify me via email or RSS

Author Corner

  • Author FAQ
 
Elsevier - Digital Commons

Home | About | FAQ | My Account | Accessibility Statement

Privacy Copyright